Рейтинг топ-10 фармацевтических компаний Великобритании и Ирландии по выручке

Top 10: Pharmaceuticals Companies in UK & Ireland The UK and Ireland are home to a diverse healthcare sector, spanning global pharmaceutical companies, specialist biopharma businesses, consumer health brands and healthcare services providers. From medicines and vaccines to self-care products, rare disease treatments and pharmaceutical distribution, these companies operate across a broad range of healthcare markets and patient needs. The sector also plays a significant role in the wider life sciences ecosystem, supporting research and development, manufacturing, supply chains and patient access across the UK, Ireland and international markets. With global revenues running into billions of dollars, the companies featured in this ranking reflect the scale and reach of healthcare businesses operating across the region. Healthcare Digital takes a look at the Top 10 pharmaceutical companies in the UK and Ireland, ranked by annual revenue. 10. Amarin HQ: Dublin, Ireland Revenue: US$213.65m CEO: Aaron Berg Amarin is a specialist biopharmaceutical company focused on cardiovascular care and reducing the risk of cardiovascular events. Its work is centred on lipid science and addressing residual cardiovascular risk, particularly among patients with elevated triglycerides. The company’s cardiovascular research is supported by more than 500 scientific publications, more than 70 medical society recommendations and approvals for cardiovascular risk reduction in more than 50 countries. Through its work on VASCEPA/VAZKEPA (icosapent ethyl), Amarin aims to improve cardiovascular outcomes and expand access to evidence-based treatment. 9. Alliance Pharma HQ: Chippenham, UK Revenue: US$242m CEO: Nick Sedgwick Alliance Pharma is focused on helping people improve their health and wellbeing through trusted brands. The company holds marketing rights to approximately 80 consumer healthcare brands and prescription medicines, with products sold in more than 100 countries. Originating in the UK more than 20 years ago, Alliance has grown into a global business employing around 290 people. Its portfolio and international distribution network support patients, consumers and healthcare providers across multiple markets. 8. Keenova Therapeutics HQ: Dublin, Ireland Revenue: US$1.4bn CEO: Sigurdur Olafsson. As a therapeutics company, Keenova focused on specialty treatments for complex and under-addressed conditions. Its portfolio spans immunology, urology and men’s health, orthopedics, critical care and paediatric endocrinology, with 12 products available in the US. Supported by 1,600 global employees, Keenova combines medicines with patient access programmes, care hubs and clinical support. Its approach integrates real-world evidence into R&D while maintaining quality across sourcing, manufacturing and distribution to improve treatment access and outcomes. 7. Uniphar HQ: Dublin, Ireland Revenue: US$2.9bn CEO: Ger Rabbette Uniphar is a top healthcare services company supporting pharmaceutical and medical technology manufacturers across Europe and global markets. Its services help improve patient access to medicines through specialised expertise in distribution, sourcing, market access and pharmaceutical services. Uniphar works with more than 200 pharmaco-medical manufacturers, supported by a global workforce of 3,600 employees and operations delivering to more than 160 countries. Its Uniphar Pharma division provides services across the pharmaceutical product lifecycle, while Uniphar Medtech supports medical device manufacturers across 21 markets. 6. Hikma Pharmaceuticals HQ: London, UK Revenue: US$3.35bn CEO: Said Darwazah A global pharmaceutical company with a strong presence across Europe, North America and the Middle East and North Africa is Hikma. Founded in 1978, it supplies more than 825 generic, specialty and branded products through three businesses – Injectables, Branded and Hikma Rx. Its 29 manufacturing facilities and three R&D hubs support the development and reliable supply of medicines. With a focus on quality, innovation and access, Hikma helps expand treatment options and support healthcare systems worldwide. 5. Perrigo HQ: Dublin, Ireland Revenue: US$4.3bn CEO: Albert Manzone Perrigo is a leading self-care company focused on making trusted health and wellness solutions accessible to consumers. With a history dating back to 1887, it provides products designed to prevent and treat self-managed conditions across major global markets. The company offers more than 13,000 stock keeping units and more than 3,000 product formulations, supported by around 9,000 employees. Its consumer-focused portfolio spans multiple categories, geographies and price points, helping meet growing demand for affordable, reliable self-care solutions. 4. Jazz Pharmaceuticals HQ: Dublin, Ireland Revenue: US$4.3bn CEO: Renee Gala As a specialist biopharmaceutical company, Jazz Pharmaceuticals develops medicines for people living with rare and complex diseases. Its portfolio spans rare sleep disorders, rare epilepsies and oncology, addressing conditions where treatment options can be limited. With established expertise in sleep medicine, it’s expanding its work in rare epilepsies and cancers, including small cell lung cancer, acute leukaemias and rare complications of stem cell transplantation. The company operates or partners across nearly 75 countries, combining patient-focused research and development. 3. Haleon HQ: Weybridge, UK Revenue: US$14bn CEO: Brian McNamara A top consumer health company in the UK and Ireland is Haleon, focused exclusively on improving everyday health. Its portfolio spans six categories – oral health, vitamins and supplements, respiratory health, pain relief, digestive health and therapeutic skin health. Its brands, including Sensodyne, Centrum, Panadol and Advil, are trusted by more than one billion consumers globally. Haleon combines scientific research, clinical testing and consumer understanding to develop accessible health products that help people manage everyday conditions and support healthier lives. 2. GSK HQ: London, UK Revenue: US$40bn CEO: Luke Miels GSK is a key pharmaceutical company in the UK and Ireland, with a global portfolio spanning specialty medicines, vaccines and general medicines. The company focuses on four core therapeutic areas – respiratory, immunology and inflammation, oncology, HIV and infectious diseases – using its expertise in the immune system alongside technologies to develop treatments and prevent disease. GSK has one of the broadest vaccine portfolios in the industry, delivering hundreds of millions of doses each year, while its medicines support patients with conditions ranging from asthma and cancer to HIV and autoimmune diseases. Its global manufacturing network of 33 medicines and vaccine sites produced and delivered 1.64 billion packs of medicines and 389 million vaccine doses in 2025. With 58 assets in its pipeline, GSK is investing in research and development to strengthen its position in global healthcare. 1. AstraZeneca HQ: Cambridge, UK Revenue: US$58.7bn CEO: Pascal Soriot AstraZeneca is a leading biopharmaceutical company in the UK and Ireland, with a major presence across the life sciences ecosystem and a broad portfolio spanning oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, rare diseases, vaccines and immune therapies. Its UK operations include five sites, including the company’s second-largest manufacturing site globally, supporting research, development, manufacturing and innovation. In 2024, AstraZeneca contributed £8.8bn (US$11.9bn) in Gross Value Added to the UK economy through its operations, supply chain and employee spending, while generating around £12bn (US$16.2bn) in UK sales to global markets. The company also supports more than 700 early-career roles, including apprenticeships, industrial placements and PhD positions. Through partnerships with the NHS, universities and other organisations, AstraZeneca is also working to improve prevention, treatment and patient outcomes while advancing the UK’s position as a global life sciences hub.